1. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.
- Author
-
Kimby E, Treon SP, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA, Johnson S, LeBlond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone M, and Bladé J
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Bence Jones Protein analysis, Bone Marrow Transplantation adverse effects, Combined Modality Therapy, Disease Progression, Female, Humans, Immunoglobulin M analysis, International Cooperation, Male, Prognosis, Risk Assessment, Secondary Prevention, Severity of Illness Index, Survival Analysis, Treatment Failure, Treatment Outcome, United States, Waldenstrom Macroglobulinemia therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow Transplantation methods, Waldenstrom Macroglobulinemia diagnosis, Waldenstrom Macroglobulinemia mortality
- Abstract
This report by an international consensus panel updates current recommendations for defining clinical response in Waldenstrom's macroglobulinemia (WM). The previously published response criteria incorporated parameters for monoclonal protein reduction and/or improvement of marrow and nodal involvement, and included definitions of complete and partial remissions. The criteria have been updated to include minor response and stable disease categories. In addition, the criteria now recognize that delayed responses after treatment with nucleoside analogues and biologic agents and the time point for assessing response in patients with WM should be considered so as to not miss or miscategorize a response. The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease.
- Published
- 2006
- Full Text
- View/download PDF